Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation.
Level 5 - mechanism / opinion, no new human data
Bench research / in vitro cell culture and biochemical study
PubMed 9830016 · doi:10.1074/jbc.273.49.32730
What was done
The authors purified and characterized an extracellular metalloprotease secreted by the BV-2 microglial cell line that degrades amyloid beta-protein (Abeta). They assessed degradation of endogenous and synthetic Abeta across picomolar to nanomolar concentrations in the presence of insulin, IDE inhibitors, and following IDE antibody immunodepletion. They also evaluated the presence of intact IDE in BV-2 conditioned media and in human cerebrospinal fluid from normal and Alzheimer's disease subjects, and tracked time-dependent Abeta oligomerization.
What was found
The Abeta-degrading protease was identified as insulin-degrading enzyme (IDE). Degradation of picomolar to nanomolar Abeta was completely prevented by insulin and two other IDE inhibitors, and immunodepletion of IDE abolished degradation activity (no numerical degradation rates or effect sizes reported in abstract). Intact IDE was confirmed in human CSF from normal and Alzheimer's subjects. IDE activity was also associated with time-dependent oligomerization of synthetic Abeta in conditioned media, which was prevented by three IDE inhibitors.
Why it matters
This paper identifies IDE as an extracellular protease capable of degrading secreted Abeta, providing a direct biochemical link between insulin metabolism and amyloid clearance relevant to Alzheimer's disease pathogenesis.
Limits
The findings are derived primarily from in vitro cell culture and biochemical assays, which may not reflect complex in vivo clearance dynamics. The abstract does not report quantitative kinetic rates, variance metrics, or the sample size of the human CSF specimens analyzed.
Cited by
- supports Insulin-degrading enzyme (IDE) degrades both insulin and beta-amyloid.